ASTRAZENECA PHARMA INDIA LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,122 INR | -0.66% |
|
-4.96% | +10.91% |
| May. 28 | Astrazeneca Pharma India's Net Profit Rises in Fiscal Q4 | MT |
| May. 27 | AstraZeneca Pharma India Limited Announces Resignation of Ankush Nandra as Non-Executive Director | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Companyâs DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Sector
Pharmaceuticals
Calendar
2024-08-11
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +10.91% | 1.85B | |
| +40.73% | 739B | |
| +31.67% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +14.40% | 240B | |
| +9.45% | 210B | |
| -4.91% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- ASTRAZEN Stock
- News AstraZeneca Pharma India Limited
- Astrazeneca Pharma India Appoints Managing Director
